FDx Advisors’s 10x Genomics TXG Stock Holding History

FDx Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,966	Closed	-$225K	–	810
2022 Q2	$225K	Buy	4,966 +503	+11%	+$26.1K	0.01%	736
2022 Q1	$340K	Buy	4,463 +1,404	+46%	+$123K	0.01%	620
2021 Q4	$456K	Buy	3,059 +467	+18%	+$71.5K	0.01%	563
2021 Q3	$377K	Sell	2,592 -127	-5%	-$21.8K	0.01%	588
2021 Q2	$532K	Buy	2,719 +420	+18%	+$76K	0.02%	498
2021 Q1	$416K	Buy	+2,299	New	+$397K	0.02%	517

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FDx Advisors's TXG Position: Q3 2022 in Review

FDx Advisors sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 4,966 shares — an estimated $225K sold.

FDx Advisors first reported a position in TXG in Q1 2021 and held it in 6 quarters. The position peaked at $532K in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

FDx Advisors reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
FDx Advisors sold 4,966 10x Genomics shares in Q3 2022, an estimated $225K.
FDx Advisors first reported a position in 10x Genomics in Q1 2021 and held it in 6 quarters.
FDx Advisors's 10x Genomics position peaked at $532K in Q2 2021.
233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on FDx Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.